Ukraine

AI Citation Summary

• Country: Ukraine
• Product line: Medical devices
• Regulator / source: Market characteristics: Pre-war medical device market was approximately USD 700–900 million, with high import dependency (~80%). Since the outbreak of full-scale war in February 2022, the market has contracted significantly, but humanitarian aid, military medical needs, and post-war reconstruction are generating new market opportunities. Ukraine is an EU candidate state (formally granted candidacy in June 2022), and the regulatory framework is aligning toward EU MDR. International aid organizations (WHO, UNICEF, USAID, etc.) are active; the proportion of products entering through humanitarian channels is rising.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Registration Timelines
• Key fees: Market characteristics: Pre-war medical device market was approximately USD 700–900 million, with high import dependency (~80%). Since the outbreak of full-scale war in February 2022, the market has contracted significantly, but humanitarian aid, military medical needs, and post-war reconstruction are generating new market opportunities. Ukraine is an EU candidate state (formally granted candidacy in June 2022), and the regulatory framework is aligning toward EU MDR. International aid organizations (WHO, UNICEF, USAID, etc.) are active; the proportion of products entering through humanitarian channels is rising.
• Local requirement: Ukraine medical-device entry should be separated into Ukrainian conformity assessment and Ministry of Health / State Service channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 37–40 million (post-February 2022, actual in-country population fluctuates significantly due to large-scale displacement; pre-war population was approximately 44 million)
• Healthcare system: The National Health Service of Ukraine (NHS Ukraine / НСЗУ, Національна служба здоров'я України) is the core, with public healthcare reform (Medreform) underway since 2018. Public hospitals dominate; private medical services are growing. Medical resources are unevenly distributed between the east and west; significant healthcare infrastructure has been damaged during the war.
• Market characteristics: Pre-war medical device market was approximately USD 700–900 million, with high import dependency (~80%). Since the outbreak of full-scale war in February 2022, the market has contracted significantly, but humanitarian aid, military medical needs, and post-war reconstruction are generating new market opportunities. Ukraine is an EU candidate state (formally granted candidacy in June 2022), and the regulatory framework is aligning toward EU MDR. International aid organizations (WHO, UNICEF, USAID, etc.) are active; the proportion of products entering through humanitarian channels is rising.
• Regulatory maturity: Medium-low. The regulatory framework has historically been influenced by the Soviet GOST system and has been moving toward EU MDR alignment in recent years. Enforcement capacity has been somewhat reduced during the war, but the basic regulatory framework remains operational. EU candidate status will drive deep restructuring of the regulatory system over the medium term.

Market-Entry Logic

Ukraine medical-device entry should be separated into Ukrainian conformity assessment and Ministry of Health / State Service channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	Ukrainian conformity assessment and Ministry of Health / State Service channels	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	NHSU, Medical Procurement of Ukraine, donor procurement and private providers	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	local importers, donor-funded suppliers, public hospitals, diagnostic networks and multinational medtech companies	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: war-related supply disruption, humanitarian procurement, EU alignment, local distributor resilience, currency/payment risk and reconstruction-driven demand are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authorities

• Competent Authority: Ministry of Health of Ukraine (МОЗ, Міністерство охорони здоров'я України) and its subordinate agency, the State Service of Ukraine on Medicines and Narcotics Control (Держлікслужба / ДКЛП, Державна служба з лікарських засобів та контролю за наркотиками)
• Official portals:
  • Ministry of Health: https://moz.gov.ua
  • State Service on Medicines: https://www.dls.gov.ua
  • E-services platform (some services migrated to the Diia government platform): https://diia.gov.ua
• Key regulations:
  • Technical Regulations on Medical Devices (Технічний регламент щодо медичних виробів), Cabinet of Ministers Resolution No. 753 (2013), based on the EU MDD 93/42/EEC framework
  • Technical Regulations on Active Implantable Medical Devices (Cabinet Resolution No. 754, 2013)
  • Technical Regulations on IVD Medical Devices (Cabinet Resolution No. 754, corresponding to EU IVDD)
  • State Registration Procedure for Medical Devices (Ministry of Health order)
  • Note: Certain regulatory implementing rules have been adjusted since 2022; a number of temporary exemption provisions have been issued during the wartime period. Verify the latest applicable texts.

Important context: Ukraine formally became an EU candidate state in June 2022, initiating a long-term process of transitioning the regulatory framework toward EU MDR/IVDR. In the short term (2024–2027), the current national regulations (based on the EU MDD framework) remain the primary applicable rules, but legislation drafts aligning with EU MDR are in progress. Monitor updates from the Ministry of Health and EU–Ukraine coordination mechanisms.

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Notes
Клас I / Class I	Low risk	EU MDD Class I / FDA Class I	General devices; some require only notification
Клас IIа / Class IIa	Medium-low risk	EU MDD Class IIa / FDA Class II	Requires Notified/Authorized Body involvement
Клас IIб / Class IIb	Medium-high risk	EU MDD Class IIb / FDA Class II	More rigorous review
Клас III / Class III	High risk	EU MDD/MDR Class III / FDA Class III	Implants, high-risk devices

Classification rules reference EU MDD Annex IX rules (not EU MDR, as the current regulation is based on MDD). Transitioning toward EU MDR classification rules is underway; during the transition, dual-track classification may apply in some cases.

Registration Pathway

Pathway for Foreign Manufacturers

1. Appoint a Ukrainian Authorized Representative (Уповноважений Представник)

   • Foreign manufacturers cannot apply directly to the Ministry of Health/Держлікслужба for registration
   • A legal entity registered in Ukraine must be appointed as Authorized Representative
   • The Authorized Representative bears legal compliance responsibility within Ukraine

2. Prepare notarized and authenticated documents

   • All foreign-language documents must be translated into Ukrainian by an authorized translation agency
   • Originals must be notarized + authenticated by the country's ministry of foreign affairs + legalized by the Ukrainian embassy (or Apostille under the Hague Convention)
   • Note: During the war, some consular services have been restricted; the legalization chain may take longer

3. Prepare the technical documentation (Реєстраційне досьє)

   • Prepare technical documentation in the format required by the Ministry of Health
   • If CE marking is already held, the EU MDD/MDR technical file can serve as the basis with adaptations
   • Must include: product description, technical specifications, test reports, risk analysis (ISO 14971), and clinical evaluation

4. Submit the registration application to Держлікслужба

   • Submit Ukrainian-language technical documentation and application form
   • Pay the state registration fee
   • Держлікслужба conducts administrative review and technical assessment

5. Obtain the State Registration Certificate (Реєстраційне посвідчення)

   • A registration certificate is issued upon successful review, with a validity period noted (typically 5 years)
   • The registration certificate is the basis for lawful market placement and importation

Key Prerequisites

• Valid Ukrainian Authorized Representative agreement (Ukrainian-language version required)
• Complete Ukrainian-language technical documentation (certified translation)
• ISO 13485 certificate or equivalent QMS documentation (current)
• Certificate of Free Sale (CFS) (notarized + legalized)
• If CE marking is held, include a certified Ukrainian translation of the Declaration of Conformity

Registration Dossier Requirements

• ISO 13485 certificate (current; certified Ukrainian translation required)
• Certificate of Free Sale (CFS) (notarized + Apostille or consulate legalization; Ukrainian translation)
• CE Declaration of Conformity (DoC) (if available; Ukrainian translation required)
• Notified Body certificate (if CE marked; for Class IIa/IIb/III)
• Device description and intended purpose (Ukrainian version)
• Technical specifications (in Ukrainian; includes performance parameters, materials list, etc.)
• Risk analysis file (ISO 14971; summary acceptable; in Ukrainian)
• Test reports (electrical safety, EMC, etc.; from internationally recognized laboratories)
• Biocompatibility report (for products in contact with the human body)
• Clinical evidence (clinical evaluation report or equivalent; Class III may require local clinical data)
• IFU / Instructions for Use (Ukrainian version; must comply with Ministry of Health format requirements)
• Label specimens (Ukrainian-language labels)
• Letter of Authorization for Authorized Representative (notarized + legalized; in Ukrainian)
• Proof of legal entity for manufacturer (notarized + legalized; Ukrainian translation)
• Registration application form (per Держлікслужба format)

Common pitfall: Ukraine has strict requirements for certified translations and legalization chains. Documents that do not conform to the Ministry of Health's prescribed format are the primary cause of rejection. During the war, some translation agencies and notary offices have been operating with reduced capacity; verify service availability in advance.

Registration Timelines

Stage	Official Timeframe	Practical Reference
Document preparation (including translation and notarization)	—	2–4 months
Держлікслужба administrative review	20 business days	1–3 months (including supplementary information)
Technical assessment (Class IIa/IIb/III)	60–90 business days	3–8 months
Class I notification	20 business days	1–3 months
Total timeline reference (Class IIb/III)	—	6–18 months

Practical note: During the war, Держлікслужба staffing and office arrangements have been affected, making actual review timelines less predictable. Some processes have migrated to electronic systems (Diia platform), but paper document submission remains the primary method. Use a local regulatory consultant to track application progress in real time.

Registration Costs

Item	Estimated Cost (USD)
State registration fee (Class I)	~50–200
State registration fee (Class IIa/IIb)	~200–600
State registration fee (Class III)	~500–1,500
Ukrainian translation (full technical dossier)	2,000–8,000 (depending on volume)
Notarization + legalization fees	500–2,000
Authorized Representative annual fee	2,000–8,000/year
Local regulatory consultant fee	2,000–6,000
Total budget reference (Class IIb, single device)	~8,000–20,000

Note: Ukrainian registration costs are among the lower end in Europe. During the war, UAH/USD exchange rate fluctuations mean USD pricing helps control currency risk.

Local Agent / Marketing Authorization Holder Requirements

• Local agent mandatory: Yes. Foreign manufacturers must appoint a legal entity registered in Ukraine as Authorized Representative.
• Representative qualifications:
  • Must be a legal entity registered in the Ukrainian Business Register
  • Must be registered as an Authorized Representative with Держлікслужба
  • Responsible for maintaining technical documentation, reporting adverse events, and oversight of compliance
  • During the war, the representative's business continuity (BCP) must be specifically assessed
• Marketing authorization holder rules:
  • The registration certificate (Реєстраційне посвідчення) may be issued in the Authorized Representative's name or the manufacturer's name (depending on the application approach)
  • If the Authorized Representative ceases operations due to the war, immediately initiate a variation application
  • Practical recommendation: Prefer distributors or representatives with backup operations in western Ukraine (e.g., Lviv) or abroad to improve business continuity

Import Requirements

• Import permit: Importation requires a valid registration certificate; some product categories (containing radioactive materials, controlled substances) may require additional permits
• Customs requirements:
  • Customs clearance requires: registration certificate, commercial invoice, packing list, Ukrainian-language labels
  • During the war, Ukraine has implemented certain import facilitation measures (especially for medical supplies), including some duty exemptions
  • Humanitarian aid devices have a simplified import procedure (coordinated by WHO/UN)
• Labeling language: Ukrainian is mandatory; must include: product name (in Ukrainian), manufacturer information, Authorized Representative information, lot/serial number, expiry date, safety warnings, and storage conditions

Post-Market Surveillance

• Adverse event reporting (Повідомлення про інциденти):
  • Serious adverse events must be reported to Держлікслужба within 15 business days
  • Immediately life-threatening events must be reported within 72 hours
  • Electronic reporting channels are preferred during the war (physical infrastructure is affected)
• Recall rules: Recalls must be executed per Держлікслужба requirements; public notices must be issued and progress reported
• Periodic safety reports: Class IIb/III products must periodically submit safety update reports (frequency per EU MDD requirements)
• Market surveillance: Держлікслужба enforcement capacity is somewhat reduced during wartime, but serious safety incidents will still prompt action

Renewal Requirements

• Registration certificate validity: Typically 5 years
• Renewal timing: Submit a renewal application 6 months before expiry; submit updated technical documentation
• Variation notifications: Significant design changes, manufacturer or Authorized Representative changes must be reported to Держлікслужба before the change takes effect
• EU MDR transition impact: As Ukraine advances its alignment with EU MDR, existing MDD-based registration certificates may require re-application once the transition period ends (timeline TBD; monitor legislative developments)

Special Regulatory Requirements

• UDI:
  • Ukraine has not yet established a local UDI system; as an EU candidate, a UDI framework compatible with EUDAMED is expected to be adopted in the future
  • EU UDI labeling is currently accepted in Ukraine; there is no mandatory local UDI requirement
• Local testing:
  • Certain product categories (e.g., electrical safety, EMC) may require local verification testing at Ukrainian-accredited laboratories
  • During the war, local laboratory capacity has been affected; Держлікслужба has shown some flexibility in accepting international test reports
  • Radiation-emitting devices must obtain an additional permit from the nuclear regulatory authority (ДАРН / SNRIU)
• EU candidate status implications:
  • Ukraine is advancing regulatory harmonization with the EU under the EU-Ukraine Association Agreement; it is anticipated that EU MDR CE marking will be progressively accepted as a registration prerequisite over the medium term (similar to a mutual recognition arrangement)
  • Monitor developments in the medical device regulatory dialogue under the EU-Ukraine Association Agreement framework
• Wartime special policies:
  • Since 2022, the Ukrainian Cabinet and Ministry of Health have issued multiple temporary exemption orders allowing certain emergency medical devices to enter the market through simplified procedures (especially those on WHO/UN lists)
  • Check the latest Ministry of Health announcements to confirm whether simplified procedures apply

Market Access Channels

• Public hospital procurement (ProZorro): Ukraine's public procurement uses the ProZorro electronic tendering platform (https://prozorro.gov.ua), which is highly transparent and open to foreign suppliers. A valid registration certificate is sufficient to participate in tenders. During the war, government procurement budgets for medical devices have increased significantly (supported by international aid funds); defense-related medical procurement has a separate channel.
• International aid channels: WHO, UNICEF, USAID, EU humanitarian aid (ECHO), and other organizations distribute medical supplies through the Ukrainian Ministry of Health. Inclusion on the qualified supplier lists of these organizations (e.g., WHO prequalification, UNICEF supplier roster) greatly increases the opportunity for products to enter Ukraine.
• Private hospitals/clinics: Private medical facilities in Kyiv, Lviv, and other regions continue to operate and have ongoing demand for imported brands; relatively flexible procurement decisions based primarily on product quality and service.
• Post-war reconstruction procurement: A large-scale medical infrastructure reconstruction need is anticipated once the war ends. The EU reconstruction fund (Ukraine Facility, planned at EUR 50 billion) will include a significant healthcare procurement component; establish relationships with the Ukrainian Ministry of Health and reconstruction agencies in advance.

Market Entry Strategy

• Recommended approach:

  • Humanitarian aid channel (highest short-term priority): Products with WHO prequalification, CE marking, or FDA 510(k) clearance can enter through simplified procedures; establishing supplier relationships with UNICEF/WHO/USAID is the fastest entry channel in the short term.
  • Formal registration pathway (medium-to-long term): Manufacturers with a long-term Ukraine strategy should initiate formal registration as early as possible (even if the market is temporarily constrained), to gain a first-mover advantage in the post-war reconstruction phase. Post-war reconstruction procurement in 2025–2027 is expected to be substantial.
  • EU MDR first: Given Ukraine's trajectory of alignment with EU MDR, products holding EU MDR CE marking will face lower future registration barriers. Use EU MDR compliance documentation as the basis to minimize additional effort for Ukrainian registration.

• Key risks:

  1. Safety and business continuity risk: Ongoing war leads to infrastructure damage, logistics disruption, and distributor operational instability; a comprehensive BCP (Business Continuity Plan) must be established, including contingency Authorized Representative arrangements
  2. Regulatory transition uncertainty: Existing MDD-based registrations may require re-application after EU MDR alignment is completed; the timeline is unclear; monitor legislative developments
  3. Payment risk: Ukraine's foreign exchange controls and banking system stability are affected by the war; reduce payment risk through letters of credit, advance payment, or international guarantee agencies
  4. Distributor stability: During the war, distributors may cease operations, relocate, or become unreachable; contracts must include representative replacement clauses and transition mechanisms
  5. Corruption risk: Ukraine is advancing market reforms but historically has high corruption indices; the ProZorro platform has significantly improved procurement transparency, but non-public procurement channels require careful navigation

• Practical tips:

  • Lviv has become Ukraine's wartime medical and commercial center; many companies base their representatives there to reduce exposure to conflict in the east
  • ProZorro tender information is fully public; strongly recommend establishing a regular monitoring mechanism to capture reconstruction procurement opportunities
  • World Bank (IBRD) and EBRD Ukraine reconstruction loan programs have an explicit preference for products certified to EU/international standards; CE-certified products receive priority
  • Consider engaging with the Ukrainian medical device industry association (АМКУ or similar) to stay current on regulatory developments and build informal communication channels with Ministry of Health officials
  • For humanitarian aid products, partnering with local NGOs or international organizations is recommended to reduce regulatory barriers and rapidly build brand recognition

Leveraging Existing CE / FDA / NMPA Approvals

Quick Reference

Certificate	Acceleration Effect	Primary Mechanism
EU CE (MDR/IVDR)	⭐⭐⭐⭐	As an EU candidate, Ukraine's regulatory framework is aligning toward EU MDR; CE marking is a powerful supporting document that significantly simplifies technical review; wartime context increases regulatory flexibility
US FDA (510(k)/PMA)	⭐⭐⭐	FDA technical documentation effectively supports Ukrainian registration; FDA approval is an important endorsement in international procurement programs
China NMPA	⭐	Ukraine does not recognize NMPA; essentially no direct benefit

EU CE (MDR/MDD/IVDR)

• Recognition mechanism: Ukraine's current Medical Devices Technical Regulations (Cabinet Resolution No. 753, 2013) are based on the EU MDD 93/42/EEC framework, closely resembling EU MDR in technical documentation structure, classification system (Class I/IIa/IIb/III), and conformity assessment procedures. EU candidate status (granted in June 2022) is further accelerating Ukraine's transition toward full EU MDR compliance. In practice, for products holding a valid CE marking (whether MDD or MDR CE), the technical review body (Держлікслужба/ДКЛП) typically uses CE technical documentation as the core reference, significantly simplifying the scope of independent technical assessment. In the wartime context (since 2022), Ukrainian regulatory authorities have demonstrated greater flexibility in the expedited procurement of emergency medical supplies, and in some cases have implemented an accelerated review track for CE-certified products, further enhancing the value of CE marking. Additionally, CE marking is one of the implicit screening criteria for product priority consideration in international aid procurement programs (World Bank, USAID, EBRD, etc.).
• Practical effect: For CE-certified products applying for Ukrainian registration, the technical documentation preparation workload is significantly reduced — most content (risk analysis, performance testing, clinical evaluation summary) can be drawn directly from the CE technical file. The main additional work consists of: (1) certified Ukrainian translation; (2) document authentication (Apostille or consulate legalization; delays possible due to wartime service disruptions); (3) format reorganization (restructured per Ukrainian Реєстраційне досьє format); and (4) appointing a Ukrainian Authorized Representative. Overall, CE-certified products can achieve a 30–50% reduction in registration timeline compared to non-CE products.
• Key considerations: The current Ukrainian regulation is based on MDD rather than MDR. When submitting MDR CE technical documentation, note format compatibility — MDR technical files fully cover MDD requirements and are generally accepted without issues, but confirm that the harmonized standards (EN standards) referenced are accepted by Ukraine as corresponding national standards (ДСТУ). Wartime disruptions to consulate legalization services may extend the Apostille/legalization chain; plan for a 6–12 month time buffer for key document authentication. Wartime exemption provisions issued since 2022 should be tracked and verified; some exemptions provide additional simplified pathways for CE-certified products.

US FDA (510(k) / De Novo / PMA)

• Recognition mechanism: There is no formal FDA mutual recognition mechanism in Ukraine's regulatory framework; FDA approval cannot directly substitute for any step in the Ukrainian registration process. However, clinical data, risk management files, and design V&V reports generated through FDA review overlap substantially with Ukrainian technical documentation requirements (ISO 14971 risk analysis, performance and safety testing) and can serve directly as supporting materials for the Ukrainian registration file. In the context of international aid procurement (USAID, World Bank programs), FDA approval is a strong endorsement of product quality, and FDA-approved products often receive priority consideration in actual procurement decisions. In the post-war reconstruction phase, internationally standard-certified products (with dual FDA/CE approval) are expected to receive substantive advantages in large Ukrainian hospital procurement tenders.
• Practical effect: FDA-certified products have significant technical documentation support (test reports and clinical data can be directly reused) and a clear commercial advantage in international aid channels. Compared to CE marking, FDA has a somewhat weaker direct regulatory acceleration effect in Ukraine (given the regulatory framework is closer to EU-based), but comparable influence at the commercial level (international procurement tenders, hospital procurement decisions). Overall rating ⭐⭐⭐, combining regulatory document reuse and commercial credibility.
• Key considerations: FDA QSR (21 CFR 820) differs from ISO 13485 required by Ukraine; ensure QMS documentation covers ISO 13485. FDA clinical data is primarily in English; certified Ukrainian translations must be provided for Ukrainian registration, with translation cost and time factored into planning.

China NMPA

• Recognition mechanism: Ukraine's regulatory framework does not recognize NMPA registration certificates and has no acceleration mechanism based on NMPA approval. Ukraine's political direction is clearly aligned toward the EU (EU candidate state); in the current geopolitical context, Chinese manufacturers entering the Ukrainian market face some political sensitivity (Ukraine–China relations have become complicated by China–Russia ties). The NMPA technical documentation structure differs significantly from Ukrainian requirements, making direct structural reuse of very limited value.
• Practical effect: Essentially no direct value for a Ukrainian registration application (⭐). Chinese post-market data could theoretically supplement safety data, but review body acceptance is low, and political sensitivity adds additional risk.
• Key considerations: Chinese brands face unique challenges in Ukraine's current market environment — on one hand, the political association with Russia through China–Russia ties raises concerns among some procurement entities; on the other hand, the price advantage carries less weight in aid procurement programs (which typically prioritize CE/FDA-certified products). Chinese manufacturers entering the Ukrainian market are advised to first complete EU CE certification and use CE marking as the primary compliance document, rather than relying solely on NMPA.

Practical Recommendations

1. CE first, Ukraine follows: The optimal pathway for manufacturers planning to enter the Ukrainian market is to first complete EU CE certification, then use the CE technical file as the basis to advance Ukrainian registration, reducing the marginal compliance cost to a minimum. CE documentation preparation and the Ukrainian application can be started in parallel immediately after the CE certificate is issued.
2. Track wartime exemptions: Wartime exemption provisions issued by the Ukrainian Ministry of Health (some of which provide additional fast-track effects for CE-certified products) are time-limited. Continuously track the latest applicable policy texts; the Authorized Representative should assume responsibility for this monitoring.
3. Advance authentication document preparation: Apostille certification and consulate legalization are significantly affected by wartime service disruptions. Prepare certified copies of key documents 6–12 months in advance and maintain a stock of pre-authenticated document copies to avoid delays when urgent applications arise.
4. Prioritize international aid channels: Products with dual CE/FDA certification should proactively position themselves in World Bank, USAID, WHO, and UNICEF procurement projects in Ukraine. These channels not only navigate some local regulatory barriers but also rapidly build brand recognition, laying the groundwork for commercial sales channels post-war.
5. Post-war reconstruction planning: While completing current wartime registration, simultaneously monitor the progress of Ukraine's EU MDR alignment legislation (expected to advance progressively through 2025–2028); plan for re-registration under the EU MDR framework in advance to avoid a market access gap when the transition period arrives.